Across TCGA pan-cancer cohorts, FAM230J RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of FAM230J’s most consistent transcriptional readouts.
The strongest signal is observed in thyroid carcinoma (THCA), where FAM230J RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FAM230J is over-expressed in tumor.
THCA are the cancer types where FAM230J tumor–normal differential expression is most reproducible.